The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Real-world diagnostic & treatment patterns in MZL: insights from a German national registry
Christian Buske, MD, University Hospital Ulm, Ulm, Germany, discusses the first results of the national registry for marginal zone lymphoma (MZL) of the German Lymphoma Alliance, emphasizing the high quality of the data collected from over 800 patients. This type of registry increases knowledge about the biological characteristics of patients while also providing insight into the treatment landscape in different regions and the effect therapeutic choices have on patient outcomes. Therefore, Prof. Buske suggests that prospective registries like this one be set up in other countries. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We in Germany have the national registry for marginal zone lymphoma. It’s a prospective registry, again, an academic registry for all comers. So you can include or we include all marginal zone lymphoma patients, independent of whether they are watch and wait or first-line treatment or later lines of treatment. The quality of data is quite high because we also do reference pathology in all cases to be really sure that we include marginal zone lymphoma patients...
We in Germany have the national registry for marginal zone lymphoma. It’s a prospective registry, again, an academic registry for all comers. So you can include or we include all marginal zone lymphoma patients, independent of whether they are watch and wait or first-line treatment or later lines of treatment. The quality of data is quite high because we also do reference pathology in all cases to be really sure that we include marginal zone lymphoma patients. So this registry has now included over 800 patients and we summarized at this meeting our first analysis about the patient characteristics and the treatment landscape in Germany.
So what we have seen are quite also interesting biological phenomena. So for instance, monoclonal gammopathy we have seen in more or less every third patient with marginal zone lymphoma, being particularly high in nodal marginal zone lymphoma where we have seen monoclonal gammopathy in more or less every second patient. I think it’s a very interesting observation. What we have seen is the PFS, the median PFS as known is excellent with over 12 years, also the overall survival. And we didn’t see any major differences between different subtypes of marginal zone lymphoma.
So when we look at the treatment landscape, the most frequently used treatment regimens or treatment concepts let’s say, are immunochemotherapy, single agent or local treatment. When we look at systemic treatment with immunochemotherapy, most of the patients, over 70% were treated with rituximab and bendamustine, around 20% with R-CHOP.
So illustrating that such a prospective registry is an excellent tool to learn more about patient characteristics or biological characteristics, I mentioned the monoclonal gammopathy, but also to understand the treatment landscape we have in different, let’s say certain individual regions in Europe, they might differ between countries, here for Germany. Such registries will also help to understand how treatment landscapes are changing with the emergence of new, particularly chemotherapy-free, approaches.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Roche/Genentech: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; BeiGene: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Research Funding, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead Sciences: Consultancy, Honoraria, Speakers Bureau; Celltrion: Consultancy, Honoraria, Research Funding, Speakers Bureau; MorphoSys: Consultancy, Honoraria, Speakers Bureau; Regeneron: Consultancy, Honoraria, Speakers Bureau; Sobi: Consultancy, Honoraria, Speakers Bureau; Lilly: Consultancy, Honoraria, Speakers Bureau; MSD: Research Funding; Amgen: Research Funding.
